Bioject's Needle-Free Delivery Technology Used by NIH
by H.S. Ayoub
BioHealthInvestor.com
Bioject Medical Technologies Inc (BJCT) announced early Thursday that the National Institutues of Health (NIH) has initiated its DNA vaccine study to prevent the H5N1 flu virus using the company's needl-free technology, Biojector 2000 (B2000).
The study aims to use the B2000 to deliver an experimental vaccine by a high pressure liquid forced through the skin, thus ensuring the comfort and safety of the test subjects and investigators.
45 total volunteers will take part in the study, 30 of whom will receive the vaccine, while the rest will receive a placebo injection.
Bioject is a very tiny company, worth slightly less than $15 on the market. It caries about $3 million in cash, and carries debts of about $900 thousand.
Revenues have been increasing steadily over the last few years, but the company's bottom line has yet to catch up.
Shares of Bioject closed at a penny above $1 on Wednesday, with a 52-week range of $0.72 to $2.
__________
BioHealthInvestor.com
Bioject Medical Technologies Inc (BJCT) announced early Thursday that the National Institutues of Health (NIH) has initiated its DNA vaccine study to prevent the H5N1 flu virus using the company's needl-free technology, Biojector 2000 (B2000).The study aims to use the B2000 to deliver an experimental vaccine by a high pressure liquid forced through the skin, thus ensuring the comfort and safety of the test subjects and investigators.
45 total volunteers will take part in the study, 30 of whom will receive the vaccine, while the rest will receive a placebo injection.
Bioject is a very tiny company, worth slightly less than $15 on the market. It caries about $3 million in cash, and carries debts of about $900 thousand.
Revenues have been increasing steadily over the last few years, but the company's bottom line has yet to catch up.
Shares of Bioject closed at a penny above $1 on Wednesday, with a 52-week range of $0.72 to $2.
__________
posted by Nico at
7:27 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home